Axsome Therapeutics Inc

NASDAQ:AXSM   4:00:00 PM EDT
75.26
-2.03 (-2.63%)
7:45:40 PM EDT: $73.07 -2.19 (-2.91%)
Earnings Announcements

Axsome Therapeutics Reports Q3 Loss Per Share Of $1.07

Published: 11/07/2022 12:53 GMT
Axsome Therapeutics Inc (AXSM) - Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update.
Axsome Therapeutics Inc Q3 Loss per Share $1.07.
Axsome Therapeutics Inc Q3 Revenue $16.8 Million.
Axsome Therapeutics - Current Cash, Along With Remaining Committed Capital From $300 Million Term Loan Facility, Sufficient to Fund Operations Into 2025.
Revenue is expected to be $22.38 Million
Adjusted EPS is expected to be -$1.07

Next Quarter Revenue Guidance is expected to be $26.87 Million
Next Quarter EPS Guidance is expected to be -$0.97

More details on our Analysts Page.